Infection status and drug resistance of Klebsiella pneumoniae septicemia in Neonatal Intensive Care Unit

Abstract

Background To analyze and evaluate the current status, clinical characteristics, and drug resistance of Klebsiella pneumoniaesepsis infection in Neonatal Intensive Care Unit (NICU), providing effective basis for timely and accurate clinical diagnosis and treatment.Methods Statistical analysis was performed on 75 cases of Enterobacteriaceae septicemia in infants admitted to NICU in a special obstetrics and gynecology hospital in Shanghai from January 2020 to June 2022. Based on bacterial identification, isolates were divided into Klebsiella pneumoniae (KP) group (n = 49) and non-KP Enterobacteriaceae group (n = 26). The infection, clinical characteristics, and bacterial resistance of the two groups of infected patients were compared.Results The increase in levels of platelet, procalcitonin, and CRP in the KP group was more significant than that in the non-KP group. The proportion of antimicrobial drug exposure in the KP group is higher than that in the non KP group. The drug resistance ofKP group to ceftazidime, ceftriaxone, cefepime, ampicillin/sulbactam, aztreonam, ciprofloxacin and compound sulfamethoxazole was significantly higher than that of the non-KP group, whereas the drug resistance rate to cefotetan, gentamycin and to bramycin was significantly lower than that of the non-KP group. 38 cases of Klebsiella pneumoniae producing ESBLs were tested for related resistance genes. The results showed that the main resistance types were SHV and TEM, with detection rates of 60.6% and 28.9%.Conclusions The high infection and drug resistance of Klebsiella pneumoniae have become a serious public health issue; Clinicians should pay attention to differential diagnosis, Reasonable selection of antibiotics to reduce the generation of drug-resistant bacteria.